NCT05341583View on ClinicalTrials.gov

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

July 23, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Ensartinib

Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.

DRUG

Placebo

Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.

Trial Locations (1)

Unknown

RECRUITING

TianJin Medical University Cancer Institute & Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05341583 - Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter